GlassScriptPhysician profile
Violette L Kaliny
NPI 1508262924
$1,785.98
in general payments reported to CMS, 2019-2025
22 companies · $975 in 2025
The $975 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.05 · 2022: $81.36 · 2023: $135 · 2024: $550 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.00 | 2023-2025 | |
| Viiv Healthcare Company | $290.45 | 2024-2025 | Apretude |
| Novo Nordisk INC | $228.05 | 2021-2025 | Wegovy, Ozempic |
| Amgen INC. | $122.41 | 2023-2025 | Otezla, Repatha, Otezla |
| Ardelyx, INC. | $115.50 | 2024-2025 | Ibsrela |
| Cranial Technologies, INC | $70.95 | 2024-2025 | Doc Band |
| Sumitomo Pharma America, INC. | $65.65 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $56.38 | 2022-2025 | Gardasil 9, Enflonsia, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.44 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $46.30 | 2024 | |
| Lilly USA, LLC | $45.80 | 2022-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $33.09 | 2024-2025 | Airsupra, Breztri |
| Exact Sciences Corporation | $28.32 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $25.82 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.70 | 2024 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $19.92 | 2025 | Zelsuvmi |
| Pfizer INC. | $19.45 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.44 | 2025 | Recorlev |
| Qiagen, LLC | $16.67 | 2025 | |
| Dexcom, INC. | $14.94 | 2023 | Dexcom G6 Transmitter |
| Phadia US INC. | $14.73 | 2024 | Immunocap |
| Sunovion Pharmaceuticals INC. | $10.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Violette Kaliny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.